Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric ...
A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As ...
Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...
Cancers driven by hiccups in RNA processing can’t hide from our immune system, according to new work published today in Cell. A cross-institutional team Fred Hutch Cancer Center and Memorial Sloan ...
Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.
How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results